From single-cell RNA expression analyses of tumor-infiltrating lymphocytes [2], we found that the Interleukin-18 (IL-18) pathway is markedly upregulated in activated and dysfunctional CD8 T cells, suggesting its promise as an immunotherapeutic target. Here, IL18 is linked to neoplasm.